EchoIQ (ASX: EIQ) Gains as AI Heart Screening Company Draws Interest

Aditi Sarkar

02 July 2026 11:42 PM AEST

EchoIQ (ASX: EIQ) Gains as AI Heart Screening Company Draws Interest

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

• Health tech mover: EchoIQ rose about 7 percent, adding an AI healthcare angle to the board.

• AI heart screening: The company uses artificial intelligence to help detect structural heart disease from echocardiogram data.

• Commercialisation focus: Value for EchoIQ is tied to adoption and regulatory progress.

EchoIQ (ASX: EIQ) rose about 7 percent to around 1.735 dollars, adding a health technology name to the top of the ASX board. The company applies artificial intelligence to the analysis of heart scans.

EchoIQ sits at the meeting point of healthcare and technology, and its share price is driven by commercial progress and regulatory milestones rather than commodity prices.

Company Overview

EchoIQ is a health technology company that applies artificial intelligence to the analysis of echocardiograms, the ultrasound scans used to assess the heart. Its technology is designed to help detect structural heart conditions earlier and more consistently.

By supporting the reading of heart scans, EchoIQ aims to help clinicians identify conditions such as aortic stenosis, where early detection can influence treatment. The company sits within the growing area of artificial intelligence applied to medical diagnostics.

What Moved the Shares

EchoIQ's move sits outside the gold and silver theme that led the session. For a health technology company, share moves usually follow commercial news, regulatory clearances or adoption milestones.

The specific driver for the session would be set out in the company's most recent ASX announcement. Readers should review that disclosure rather than tie the move to the wider market pattern.

Technology and Market

EchoIQ's platform is built to analyse heart scan data and support clinical decisions. Adoption depends on winning acceptance among healthcare providers and on securing regulatory clearances in target markets such as the United States.

As an artificial intelligence business in healthcare, the company's growth is measured through commercial agreements, the number of sites using its technology, and the regulatory approvals that allow it to expand.

Financial Context

EchoIQ's finances reflect a commercialising technology business, with spending directed at product development, regulatory work and building market presence. Cash position and funding are common areas of focus for investors.

The shares traded around 1.735 dollars on the day of the move. Current figures on revenue, commercial agreements and regulatory status should be confirmed from the company's official disclosures.

Outlook

EchoIQ's prospects rest on wider adoption of its technology and on securing clearances and commercial agreements in major markets. Growing interest in artificial intelligence in healthcare provides a supportive backdrop, while commercial and regulatory milestones give the company-specific catalysts.

AI in Medical Diagnostics

Artificial intelligence applied to medical imaging has drawn growing interest as healthcare systems look for ways to detect disease earlier and read scans more consistently. EchoIQ works in this area by supporting the analysis of echocardiograms, aiming to help clinicians identify structural heart conditions that might otherwise be missed or found late.

For a company of this kind, value builds through regulatory clearances that permit its tools to be used, and through adoption by healthcare providers. Commercial agreements and the number of sites using the technology are common measures of progress, alongside the clinical evidence that supports its use.

Risks and Considerations

Health technology companies face risks around regulation, adoption and competition. Regulatory clearances can be delayed, healthcare providers may be slow to take up new tools, and other companies are also developing artificial intelligence for medical use. Building a commercial base takes capital that may require further raising.

These considerations are general in nature. For EchoIQ's actual clearances, commercial agreements and funding position, investors should refer to the company's official disclosures.

FAQs

Q: What does EchoIQ do?

A: EchoIQ is a health technology company that applies artificial intelligence to the analysis of heart scans to help detect structural heart conditions.

Q: Why did EchoIQ shares rise?

A: The move sits outside the gold and silver theme. For a health technology company, the driver is usually commercial or regulatory news, which would appear in its latest ASX announcement.

Q: Is EchoIQ generating revenue?

A: EchoIQ is a commercialising technology business. Its current commercial status should be confirmed from official disclosures.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.